Although Pfizer started clinical trials with a goal of releasing data by the beginning of November, that has become unlikely. CEO Albert Bourla announced that the company doesn’t anticipate sharing information on its trial until about a week after the data and safety monitoring board conducts its review of the company’s phase three vaccine trial. Yourway has two decades of experience and a robust global footprint, which allows us to deliver faster turnaround times.